---
document_datetime: 2023-09-21 18:58:41
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/steps-after-cutoff/novomix-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
document_name: novomix-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
version: success
processing_time: 1.8140631
conversion_datetime: 2025-12-28 13:18:02.894344
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Procedural steps taken after granting the Marketing Authorisation

For procedures finalised after 1 September 2004 please refer to module 8B

| Scope                                                                                                                                                                           | Application number   | Type of modification 1   | Notification/ Opinion issued on 2   | Commission Decision Issued/amended on   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|--------------------------|-------------------------------------|-----------------------------------------|
| Additional presentation (Flex Pen)                                                                                                                                              | II/01                | II                       | 19.10.00                            | 29.01.01                                |
| Change in test procedure of the active substance and the medicinal product                                                                                                      | I/02                 | I                        | 15.09.00                            | -                                       |
| Withdrawal of 2 presentations (vials) with the EU numbers EU/1/00/142/001-002                                                                                                   |                      |                          |                                     | 29.01.01                                |
| Extension of shelf-life as foreseen at the time of authorisation                                                                                                                | I/03                 | I                        | 30.10.00                            | 22.01.01                                |
| Quality changes, additional facility for purification of Insulin Aspart                                                                                                         | II/0004              | II                       | 20.09.01                            | -                                       |
| Optimisation of the manufacturing process                                                                                                                                       | II/05                | II                       | 17.01.02                            | -                                       |
| Change for the deletion of the bio identity test                                                                                                                                | II/06                | II                       | 21.02.02                            | -                                       |
| Minor change of the manufacturing process of the active substance                                                                                                               | I/07                 | I                        | 21.02.02                            | -                                       |
| Withdrawal of 2 presentations with the EU numbers EU/1/00/142/003 and EU/1/00/142/003/006                                                                                       |                      |                          |                                     | 08.11.02                                |
| Additional site of manufacture and additional manufacturer/site responsible for batch release of the FlexPen finished product (Chartres, France).                               | I/08                 | I                        | 16.07.2003                          | 22.08.03                                |
| Increase of shelf life of NovoMix 30 FlexPen finished product from 18 to 24 months                                                                                              | I/09                 | I                        | 08.08.2003                          | 08.10.03                                |
| Minor changes in manufacture of the medicinal product                                                                                                                           | I/10                 | I/II                     | 25.09.03                            | -                                       |
| Qualitative change to the active substance(s)                                                                                                                                   | X/11                 | X                        | 03.06.04                            | 24.08.04                                |
| Revision of the SPC and PL to standardise the product information text for all Novo Nordisk A/S insulin products, and to reflect in the PL the results of the readability tests | II/12                | II                       | 26.02.04                            | 15.04.04                                |
| Update of sections 4.4 and 4.8 of SPC and PL                                                                                                                                    | II/13                | II                       | 26.02.04                            | 15.04.04                                |

<div style=\"page-break-after: always\"></div>

| Update of or change(s) to the pharmaceutical documentation                                                                                                                                                      | II/14   | II   | 24.03.04   |          |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|------|------------|----------|
| Update of section 4.2 and 5.1 of the SPC and PL to specify the use of NovoMix 30 in combination with metformin in patients with type 2 Diabetes mellitus that are insufficiently controlled on metformin alone. | II/15   | II   | 22.04.04   | 07.07.04 |
| Update of or change(s) to the pharmaceutical documentation                                                                                                                                                      | II/16   | II   | 22.04.04   | -        |
| Change in the specification of immediate packaging - tightening of specification limits                                                                                                                         | I/17    | Ib   | 22.06.04   | -        |